Skip to main content
Erschienen in: International Journal of Hematology 4/2024

09.02.2024 | Original Article

Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants

verfasst von: Osamu Kumano, Shinya Suzuki, Masako Yamazaki, Yoshimori An, Masahiro Yasaka, Masahiro Ieko, For the Japanese Study Group for the Assessment of Direct Oral Anticoagulants

Erschienen in: International Journal of Hematology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Age is a significant risk factor for ischemic stroke. However, the influence of aging on coagulation parameters in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOACs) remains unclear. A total of 775 samples were collected from 224 NVAF patients receiving apixaban, edoxaban or rivaroxaban. The samples were categorized into three age groups: (i) ≤ 64 years, (ii) 65–74 years, and (iii) ≥ 75 years (apixaban: N = 48, 108, 119; edoxaban: N = 63, 68, 126; rivaroxaban: N = 115, 90, 38, respectively). Coagulation parameters including fibrinogen (Fbg), factor II, factor V, factor VII, factor X, and D-dimer, were compared between the three age groups for each drug. The slopes in the correlation between drug concentrations and modified diluted prothrombin time (mdPT) were also assessed. Fbg and factor V increased with age, while factor II and factor X decreased. Factor VII and D-dimer showed no significant differences across age categories. The slope in response to drug concentrations was similar between the age groups. In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.
Literatur
1.
Zurück zum Zitat Kario K, Matsuo T. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk. 1994;1:165–71.CrossRefPubMed Kario K, Matsuo T. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk. 1994;1:165–71.CrossRefPubMed
2.
Zurück zum Zitat Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, et al. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. Ann Epidemiol. 1992;2:509–19.CrossRefPubMed Tracy RP, Bovill EG, Fried LP, Heiss G, Lee MH, Polak JF, et al. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. Ann Epidemiol. 1992;2:509–19.CrossRefPubMed
3.
Zurück zum Zitat Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol. 1996;143:665–76.CrossRefPubMed Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Am J Epidemiol. 1996;143:665–76.CrossRefPubMed
4.
Zurück zum Zitat Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995;85:3144–9.CrossRefPubMed Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995;85:3144–9.CrossRefPubMed
5.
Zurück zum Zitat Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefPubMed
6.
Zurück zum Zitat Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMed Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefPubMed
7.
Zurück zum Zitat Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.CrossRefPubMed Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.CrossRefPubMed
8.
Zurück zum Zitat Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, ENGAGE AF-TIMI 48 Investigators, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMed Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, ENGAGE AF-TIMI 48 Investigators, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefPubMed
9.
Zurück zum Zitat Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRef Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRef
10.
Zurück zum Zitat Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019;41(Suppl 1):33–9.CrossRefPubMed Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019;41(Suppl 1):33–9.CrossRefPubMed
11.
Zurück zum Zitat Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M. Newly developed modified diluted prothrombin time reagent: a multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy. Thromb Res. 2022;210:87–90.CrossRefPubMed Kumano O, Suzuki S, Yamazaki M, An Y, Yasaka M, Ieko M. Newly developed modified diluted prothrombin time reagent: a multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy. Thromb Res. 2022;210:87–90.CrossRefPubMed
12.
Zurück zum Zitat Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMed Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMed
13.
Zurück zum Zitat Lip GYP, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed Lip GYP, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed
14.
Zurück zum Zitat Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMed Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMed
15.
Zurück zum Zitat Ieko M, Komiyama Y, Yamazaki S, Katagiri H, Shimazu C, Naito S, Matsuda M, Yuki Y, Miyata K, Arai R, Kumano O, Emmi M, Yoshida T, Tanaka H, Okuhara T, Yamashita T, Sekine Y, Homma M, Kawai Y, Tohyama K. Int J Hematol. 2020;112:614–20.CrossRefPubMed Ieko M, Komiyama Y, Yamazaki S, Katagiri H, Shimazu C, Naito S, Matsuda M, Yuki Y, Miyata K, Arai R, Kumano O, Emmi M, Yoshida T, Tanaka H, Okuhara T, Yamashita T, Sekine Y, Homma M, Kawai Y, Tohyama K. Int J Hematol. 2020;112:614–20.CrossRefPubMed
16.
Zurück zum Zitat Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109:127–36.CrossRefPubMed Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost. 2013;109:127–36.CrossRefPubMed
17.
Zurück zum Zitat Castellone DD, Castillo R, Depasse F, Doyle M, Halim AB, Kitchen S et al. Determination of coagulation factor activities using the one-stage clotting assay, in: Approved Guideline, 2nd edition, Clinical and Laboratory Standards Institute, Wayne, PA, 2016. CLSI Document H48-A. Castellone DD, Castillo R, Depasse F, Doyle M, Halim AB, Kitchen S et al. Determination of coagulation factor activities using the one-stage clotting assay, in: Approved Guideline, 2nd edition, Clinical and Laboratory Standards Institute, Wayne, PA, 2016. CLSI Document H48-A.
18.
Zurück zum Zitat Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, et al. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: results of multicenter study in Japan. Thromb Res. 2020;195:158–64.CrossRefPubMed Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, et al. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: results of multicenter study in Japan. Thromb Res. 2020;195:158–64.CrossRefPubMed
19.
Zurück zum Zitat Kario K, Matsuo T, Kobayashi H, Kanai N, Hoshide S, Mitsuhashi T, et al. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol. 1998;32:444–50.CrossRefPubMed Kario K, Matsuo T, Kobayashi H, Kanai N, Hoshide S, Mitsuhashi T, et al. Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol. 1998;32:444–50.CrossRefPubMed
20.
Zurück zum Zitat Ariyo AA, Tracy CTR. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108–15.CrossRefPubMed Ariyo AA, Tracy CTR. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108–15.CrossRefPubMed
21.
Zurück zum Zitat Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–9.CrossRefPubMed Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–9.CrossRefPubMed
22.
Zurück zum Zitat Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–9.CrossRefPubMed Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–9.CrossRefPubMed
23.
Zurück zum Zitat Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–21.CrossRefPubMed Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3:514–21.CrossRefPubMed
24.
Zurück zum Zitat Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol. 2010;4:5.CrossRefPubMedPubMedCentral Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst Biol. 2010;4:5.CrossRefPubMedPubMedCentral
Metadaten
Titel
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants
verfasst von
Osamu Kumano
Shinya Suzuki
Masako Yamazaki
Yoshimori An
Masahiro Yasaka
Masahiro Ieko
For the Japanese Study Group for the Assessment of Direct Oral Anticoagulants
Publikationsdatum
09.02.2024
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 4/2024
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03712-4

Weitere Artikel der Ausgabe 4/2024

International Journal of Hematology 4/2024 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.